Listing 1 - 2 of 2 |
Sort by
|
Choose an application
Multiphasic health screening --- Periodic health examinations --- Multiphasic Screening. --- Physical Examination. --- Multiphasic health screening. --- Periodic health examinations. --- Health examinations --- Medical examinations --- Physical examinations (Medicine) --- Diagnostic services --- Automated multiphasic health testing --- Health testing, Multiphasic --- Multiphasic health testing --- Medical screening --- Examination, Physical --- Physical Examinations and Diagnoses --- Physical Exam --- Exam, Physical --- Examinations, Physical --- Exams, Physical --- Physical Examinations --- Physical Exams --- Surgical Clearance --- Independent Medical Evaluation --- Automated Multiphasic Health Testing --- Multiphasic Screenings --- Screening, Multiphasic --- Screenings, Multiphasic
Choose an application
"Many drug developers have examined new strategies for creating efficiencies in their development processes, including the adoption of genomics-based approaches. Genomic data can identify new drug targets for both common and rare diseases, can predict which patients are likely to respond to a specific treatment, and has the potential to significantly reduce the cost of clinical trials by reducing the number of patients that must be enrolled in order to demonstrate safety and efficacy. A key component of the approval of targeted therapeutics is the ability to identify the population of patients who will benefit from treatment, and this has largely hinged on the co-development and co-submission to the FDA of a companion diagnostic test. The co-development process, or the development of the test and drug for the simultaneous submission to FDA, has led to a major alteration in the way that drugs are being developed, with traditionally separate entities pharmaceutical and diagnostic companies now working in close collaboration. Refining Processes for the Co-Development of Genome-Based Therapeutics and Companion Diagnostic Tests is the summary of a workshop held by the Roundtable on Translating Genomic-Based Research for Health on February 27, 2013 to examine and discuss challenges and potential solutions for the codevelopment of targeted therapeutics and companion molecular tests for the prediction of drug response. Prior to the workshop, key stakeholders, including laboratory and medical professional societies, were individually asked to provide possible solutions to resolve the concerns raised about co-development of companion diagnostic tests and therapies. Workshop speakers were charged with addressing these solutions in their presentations by providing insight on (1) whether the proposed solutions address the problems described, (2) whether there are other solutions to propose, and (3) what steps could be taken to effectively implement the proposed solutions"--
Drug development -- United States -- Congresses. --- Gene therapy -- United States -- Congresses. --- Therapeutics -- United States -- Congresses. --- Drug development --- Gene therapy --- Human chromosome abnormalities --- Therapeutics --- Genetic Techniques --- Genetic Services --- Drug Discovery --- Diagnostic Techniques and Procedures --- Diagnostic Services --- Evaluation Studies as Topic --- Chemistry, Pharmaceutical --- Investigative Techniques --- Health Services --- Preventive Health Services --- Diagnosis --- Analytical, Diagnostic and Therapeutic Techniques and Equipment --- Health Care Facilities, Manpower, and Services --- Pharmacology --- Community Health Services --- Chemistry --- Health Care --- Natural Science Disciplines --- Biological Science Disciplines --- Disciplines and Occupations --- Genetic Testing --- Drug Design --- Drug Evaluation --- Health & Biological Sciences --- Pharmacy, Therapeutics, & Pharmacology
Listing 1 - 2 of 2 |
Sort by
|